(Reuters) - Drugmaker Forest Laboratories Inc said on Wednesday it believes that billionaire investor Carl Icahn secured one out of four board seats he was targeting in a proxy battle.
The company said Icahn nominee Pierre Legault would likely replace current director Dan Goldwasser, who serves as chairman of the compensation committee.
(Reporting by Soyoung Kim; Editing by Gerald E. McCormick)